Spondyloarthropathy

Last updated
Spondyloarthropathy
Psoriaris-Arthritis 01.jpg
Specialty Rheumatology   OOjs UI icon edit-ltr-progressive.svg

Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such, it is a class or category of diseases rather than a single, specific entity. It differs from spondylopathy, which is a disease of the vertebra itself, but many conditions involve both spondylopathy and spondyloarthropathy.

Contents

Spondyloarthropathy with inflammation is called axial spondyloarthritis . [1] In the broadest sense, the term spondyloarthropathy includes joint involvement of vertebral column from any type of joint disease, including rheumatoid arthritis and osteoarthritis, but the term is often used for a specific group of disorders with certain common features, which are often specifically termed seronegative spondylarthropathies. They have an increased incidence of HLA-B27, as well as negative rheumatoid factor and ANA. Enthesopathy is also sometimes present in association with seronegative spondarthritides[ clarify ].

Non-vertebral signs and symptoms of degenerative or other not directly infected inflammation, in the manner of spondyloarthropathies, include asymmetric peripheral arthritis (which is distinct from rheumatoid arthritis), arthritis of the toe interphalangeal joints, sausage digits, Achilles tendinitis, plantar fasciitis, costochondritis, iritis, and mucocutaneous lesions. But lower back pain is the most common clinical presentation of the causes of spondyloarthropoathies; this back pain is unique because it decreases with activity.[ citation needed ]

Seronegative spondyloarthropathy

Seronegative spondyloarthropathy (or seronegative spondyloarthritis) is a group of diseases involving the axial skeleton [2] and having a negative serostatus.

"Seronegative" refers to the fact that these diseases are negative for rheumatoid factor, [3] indicating a different pathophysiological mechanism of disease than is commonly seen in rheumatoid arthritis.

Conditions

The following conditions are typically included in the group of seronegative spondylarthropathies:

ConditionPercent of people with the
condition who are HLA-B27 positive
Axial spondyloarthritis (including ankylosing spondylitis) [4] [5]
  • Caucasians: 92% [6]
  • African-Americans: 50%
Reactive arthritis [4] [5] 60–80%
Enteropathic arthropathy or spondylitis associated with

inflammatory bowel disease [4] [5] (including Crohn's disease and ulcerative colitis)

60%
Psoriatic arthritis [4] [5] 40–50%
Isolated acute anterior uveitis 50%
Juvenile idiopathic arthritis (subtype: late-onset oligoarticular JIA)
Undifferentiated spondyloarthropathy [4] [5] (USpA)20–25%

Some sources also include Behçet's disease [ citation needed ] and Whipple's disease. [7]

Common characteristics

These diseases have the following conditions in common:

Classification

Assessment of Spondylarthritis International Society (ASAS criteria) is used for classification of axial spondyloarthritis (to be applied for patients with back pain greater than or equal to 3 months and age of onset less than 45 years). [11] It is of two broad types: [12] [13]

  1. Sacroiliitis on imaging plus 1 SpA feature, or
  2. HLA-B27 plus 2 other SpA features

Sacroiliitis on imaging: [11]

SpA features: [11]

Treatment

Many patients have more than one of the spondyloarthritis disease manifestations. Some immunosuppressive drugs have shown efficacy in more than one of the diseases, e.g. tumor necrosis factor (TNF) inhibitors. But some of the immunosuppressive drugs are particularly effective for a specific inflamed tissue and approved in only one or two of the disease entities, [14] so an interdisciplinary approach is required.

Epidemiology

Worldwide prevalence of spondyloarthropathy is approximately 1.9%. [15]

Related Research Articles

<span class="mw-page-title-main">Arthritis</span> Type of joint disorder

Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Onset can be gradual or sudden.

<span class="mw-page-title-main">Rheumatoid arthritis</span> Type of autoimmune arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves and blood. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.

Arthralgia literally means joint pain. Specifically, arthralgia is a symptom of injury, infection, illness, or an allergic reaction to medication.

<span class="mw-page-title-main">Ankylosing spondylitis</span> Type of arthritis in which there is long-term inflammation of the joints of the spine

Ankylosing spondylitis (AS) is a type of arthritis characterized by long-term inflammation of the joints of the spine typically where the spine joins the pelvis. Occasionally areas affected may include other joints such as the shoulders or hips. Eye and bowel problems may occur as well as back pain. Joint mobility in the affected areas generally worsens over time.

<span class="mw-page-title-main">HLA-B27</span> Type of antigen

Human leukocyte antigen (HLA) B27 is a class I surface antigen encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides to T cells. HLA-B27 is strongly associated with ankylosing spondylitis and other associated inflammatory diseases, such as psoriatic arthritis, inflammatory bowel disease, and reactive arthritis.

<span class="mw-page-title-main">Psoriatic arthritis</span> Long-term inflammatory arthritis

Psoriatic arthritis (PsA) is a long-term inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis. The classic feature of psoriatic arthritis is swelling of entire fingers and toes with a sausage-like appearance. This often happens in association with changes to the nails such as small depressions in the nail (pitting), thickening of the nails, and detachment of the nail from the nailbed. Skin changes consistent with psoriasis frequently occur before the onset of psoriatic arthritis but psoriatic arthritis can precede the rash in 15% of affected individuals. It is classified as a type of seronegative spondyloarthropathy.

<span class="mw-page-title-main">Uveitis</span> Inflammation of the uvea of the eye

Uveitis is inflammation of the uvea, the pigmented layer of the eye between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid. Uveitis is described anatomically, by the part of the eye affected, as anterior, intermediate or posterior, or panuveitic if all parts are involved. Anterior uveitis (iridocyclitis) is the most common, with the incidence of uveitis overall affecting approximately 1:4500, most commonly those between the ages of 20-60. Symptoms include eye pain, eye redness, floaters and blurred vision, and ophthalmic examination may show dilated ciliary blood vessels and the presence of cells in the anterior chamber. Uveitis may arise spontaneously, have a genetic component, or be associated with an autoimmune disease or infection. While the eye is a relatively protected environment, its immune mechanisms may be overcome resulting in inflammation and tissue destruction associated with T-cell activation.

<span class="mw-page-title-main">Arthropathy</span> Medical condition

An arthropathy is a disease of a joint.

<span class="mw-page-title-main">Reactive arthritis</span> Medical condition

Reactive arthritis, also known as Reiter's syndrome, is a form of inflammatory arthritis that develops in response to an infection in another part of the body (cross-reactivity). Coming into contact with bacteria and developing an infection can trigger the disease. By the time the patient presents with symptoms, often the "trigger" infection has been cured or is in remission in chronic cases, thus making determination of the initial cause difficult.

<span class="mw-page-title-main">Sacroiliitis</span> Medical condition

Sacroiliitis is inflammation within the sacroiliac joint. It is a feature of spondyloarthropathies, such as axial spondyloarthritis, psoriatic arthritis, reactive arthritis or arthritis related to inflammatory bowel diseases, including ulcerative colitis or Crohn's disease. It is also the most common presentation of arthritis from brucellosis.

<span class="mw-page-title-main">Certolizumab pegol</span> Pharmaceutical drug

Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS). The BASDAI is one of a group of classification criteria for spondyloarthropathies.

<span class="mw-page-title-main">Golimumab</span> Pharmaceutical drug

Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.

<span class="mw-page-title-main">Arthritis mutilans</span> Medical condition

Arthritis mutilans is a rare medical condition involving severe inflammation damaging the joints of the hands and feet, and resulting in deformation and problems with moving the affected areas; it can also affect the spine. As an uncommon arthropathy, arthritis mutilans was originally described as affecting the hands, feet, fingers, and/or toes, but can refer in general to severe derangement of any joint damaged by arthropathy. First described in modern medical literature by Marie and Leri in 1913, in the hands, arthritis mutilans is also known as opera glass hand, or chronic absorptive arthritis. Sometimes there is foot involvement in which toes shorten and on which painful calluses develop in a condition known as opera glass foot, or pied en lorgnette.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17 used for treatment of psoriasis

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is a patient-reported outcome (PRO) measure which assesses the quality of life of patients with ankylosing spondylitis. The ASQoL is based on the needs-based quality of life model. It is a self-administered questionnaire which contains 18 items and takes up to four minutes to complete.

<span class="mw-page-title-main">Axial spondyloarthritis</span> Medical condition

Axial spondyloarthritis is a chronic, autoinflammatory disease predominantly affecting the axial skeleton. The phrase itself is an umbrella term characterizing a diverse disease family united by shared clinical and genetic features, such as the involvement of the axial skeleton. The best-known member of the axial spondyloarthritis disease family is ankylosing spondylitis. The 2009 introduction of the expression axial spondyloarthritis made it possible to refer to (1) less severe forms of spondylitis, (2) the early phase of ankylosing spondylitis and (3) ankylosing spondylitis itself collectively.

In radiology, a Romanus lesion is the erosion of the anterior and posterior vertebral endplates in patients with an inflammatory spondyloarthropathy – such as ankylosing spondylitis or an enteropathic arthropathy. The anterior erosion in particular causes a loss of anterior vertebral body concavity, causing the vertebra to display a squared contour or even a barrel-shape. Healing of the erosion results in a sclerotic increase in density causing what is known as a shiny corner sign, which can later result in syndesmophyte formation. It is most easily diagnosed using MRI, compared to conventional radiography.

Diagnostic delay is the time interval between the onset of symptoms and confirmed diagnosis of a disease. For a variety of reasons, including the mitigation of disease severity and financial expense, it is desirable for this delay to be minimized.

Ross E. Petty is a Canadian pediatric rheumatologist. He is a professor emeritus in the Department of Pediatrics at the University of British Columbia and a pediatric rheumatologist at BC Children’s Hospital in Vancouver, Canada. He established Canada’s first formal pediatric rheumatology program at the University of Manitoba in 1976, and three years later, he founded a similar program at the University of British Columbia.

References

  1. Mosby's Medical Dictionary, 8th edition. © 2009
  2. Howe HS, Zhao L, Song YW, et al. (February 2007). "Seronegative spondyloarthropathy--studies from the Asia Pacific region" (PDF). Ann. Acad. Med. Singap. 36 (2): 135–41. doi:10.47102/annals-acadmedsg.V36N2p135. PMID   17364081.
  3. "Seronegative Spondyloarthropathies: Joint Disorders: Merck Manual Professional" . Retrieved 2008-12-15.
  4. 1 2 3 4 5 Luong AA, Salonen DC (August 2000). "Imaging of the seronegative spondyloarthropathies". Curr Rheumatol Rep. 2 (4): 288–96. doi:10.1007/s11926-000-0065-z. PMID   11123073. S2CID   21358459.
  5. 1 2 3 4 5 6 7 8 9 10 11 Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series) . Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN   978-0-7817-7153-5.
  6. Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy Workup Author: Lawrence H Brent. Chief Editor: Herbert S Diamond. Updated: Apr 19, 2011
  7. Várvölgyi C, Bubán T, Szakáll S, et al. (April 2002). "Fever of unknown origin with seronegative spondyloarthropathy: an atypical manifestation of Whipple's disease". Ann. Rheum. Dis. 61 (4): 377–8. doi:10.1136/ard.61.4.377. PMC   1754069 . PMID   11874851.
  8. Shankarkumar U, Devraj JP, Ghosh K, Mohanty D (2002). "Seronegative spondarthritis and human leucocyte antigen association". Br. J. Biomed. Sci. 59 (1): 38–41. doi:10.1080/09674845.2002.11783633. PMID   12000185. S2CID   32666163.
  9. Maria Antonietta D'Agostino, MD; Ignazio Olivieri, MD (June 2006). "Enthesitis". Best Practice. 20 (3): 473–486. doi:10.1016/j.berh.2006.03.007. PMID   16777577.
  10. The Free Dictionary (2009). "Enthesitis" . Retrieved 2010-11-27.
  11. 1 2 3 Lipton, Sarah; Deodhar, Atul (2012). "The new ASAS classification criteria for axial and peripheral spondyloarthritis: promises and pitfalls". International Journal of Clinical Rheumatology . 7 (6): 675–682. doi:10.2217/ijr.12.61.
  12. Rudwaleit, M; Landewe, R; van der Heijde, D; Listing, J; Brandt, J; Braun, J; Burgos-Vargas, R; Collantes-Estevez, E; Davis, J; Dijkmans, B; Dougados, M; Emery, P; van der Horst-Bruinsma, I E; Inman, R; Khan, M A; Leirisalo-Repo, M; van der Linden, S; Maksymowych, W P; Mielants, H; Olivieri, I; Sturrock, R; de Vlam, K; Sieper, J (17 March 2009). "The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal". Annals of the Rheumatic Diseases. 68 (6): 770–776. doi:10.1136/ard.2009.108217. PMID   19297345. S2CID   34185040.
  13. Rudwaleit, M; van der Heijde, D; Landewe, R; Listing, J; Akkoc, N; Brandt, J; Braun, J; Chou, C T; Collantes-Estevez, E; Dougados, M; Huang, F; Gu, J; Khan, M A; Kirazli, Y; Maksymowych, W P; Mielants, H; Sorensen, I J; Ozgocmen, S; Roussou, E; Valle-Onate, R; Weber, U; Wei, J; Sieper, J (17 March 2009). "The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection". Annals of the Rheumatic Diseases. 68 (6): 777–783. doi: 10.1136/ard.2009.108233 . PMID   19297344.
  14. Brüner, Mads; Dige, Anders; Loft, Anne Gitte; Laurberg, Trine Bay; Agnholt, Jørgen Steen; Clemmensen, Kåre; McInnes, Iain; Lories, Rik; Iversen, Lars; Hjuler, Kasper Fjellhaugen; Kragstrup, Tue Wenzel (2021). "Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment". Autoimmunity Reviews. 20 (2): 102731. doi:10.1016/j.autrev.2020.102731. PMID   33326852. S2CID   229300462.
  15. Hoving JL, Lacaille D, Urquhart DM, Hannu TJ, Sluiter JK, Frings-Dresen MH (2014). "Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis". The Cochrane Database of Systematic Reviews. 11 (11): CD010208. doi: 10.1002/14651858.CD010208.pub2 . PMID   25375291.